药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2014年
5期
405-408
,共4页
金刚藤口服液%免疫调节%治疗%慢性盆腔炎
金剛籐口服液%免疫調節%治療%慢性盆腔炎
금강등구복액%면역조절%치료%만성분강염
Bullbrier Polysaccharide%CPID%Treatment%Immunoregulation
目的：从免疫调节角度研究金刚藤口服液对大鼠慢性盆腔炎的治疗作用。方法：选择未交配的 SPF 级雌性 SD 大鼠60只，随机分为空白组、模型组、阳性（金刚藤胶囊）组、金刚藤口服液低、中、高剂量组。实验第1天，除空白组外，其余各组大鼠用戊巴比妥麻醉，采用双侧输卵管注入30%苯酚胶浆生理盐水溶液，制作大鼠盆腔炎模型。造模后正常组和模型组 ig 给予纯净水，其余各组 ig 给予药物，其中阳性组日给药量为540 mg·kg-1，金刚藤口服液低、中、高剂量组日给药量分别为：15 mg·kg-1、30 mg·kg-1、60 mg·kg-1，每天1次，共 ig 治疗20天。第21天断颈处死动物，ELISA 法测定各实验组大鼠血浆 IgA、IgM 和 IgG 含量；剖取子宫，称重后做病理形态分析。结果：与正常组比较，模型组大鼠子宫重量系数[（11.7±1.92） mg·g-1]极显著增大（P<0.01），血浆IgA[（27.99±5.49）μg·mL-1]、IgM[（21.94±1.98）μg·mL-1]和 IgG[（4.85±1.97）μg·mL-1]含量均有极显著减少（P<0.01）；子宫炎症性病变显著加重；与模型组比较，金刚藤口服液组可显著减小大鼠子宫重量系数（P<0.05），增加血浆 IgA、IgM 和 IgG 含量（P<0.05），且能减轻子宫炎症性病变。结论：金刚藤口服液可通过调节大鼠血浆免疫球蛋白浓度而对慢性盆腔炎产生治疗作用。
目的：從免疫調節角度研究金剛籐口服液對大鼠慢性盆腔炎的治療作用。方法：選擇未交配的 SPF 級雌性 SD 大鼠60隻，隨機分為空白組、模型組、暘性（金剛籐膠囊）組、金剛籐口服液低、中、高劑量組。實驗第1天，除空白組外，其餘各組大鼠用戊巴比妥痳醉，採用雙側輸卵管註入30%苯酚膠漿生理鹽水溶液，製作大鼠盆腔炎模型。造模後正常組和模型組 ig 給予純淨水，其餘各組 ig 給予藥物，其中暘性組日給藥量為540 mg·kg-1，金剛籐口服液低、中、高劑量組日給藥量分彆為：15 mg·kg-1、30 mg·kg-1、60 mg·kg-1，每天1次，共 ig 治療20天。第21天斷頸處死動物，ELISA 法測定各實驗組大鼠血漿 IgA、IgM 和 IgG 含量；剖取子宮，稱重後做病理形態分析。結果：與正常組比較，模型組大鼠子宮重量繫數[（11.7±1.92） mg·g-1]極顯著增大（P<0.01），血漿IgA[（27.99±5.49）μg·mL-1]、IgM[（21.94±1.98）μg·mL-1]和 IgG[（4.85±1.97）μg·mL-1]含量均有極顯著減少（P<0.01）；子宮炎癥性病變顯著加重；與模型組比較，金剛籐口服液組可顯著減小大鼠子宮重量繫數（P<0.05），增加血漿 IgA、IgM 和 IgG 含量（P<0.05），且能減輕子宮炎癥性病變。結論：金剛籐口服液可通過調節大鼠血漿免疫毬蛋白濃度而對慢性盆腔炎產生治療作用。
목적：종면역조절각도연구금강등구복액대대서만성분강염적치료작용。방법：선택미교배적 SPF 급자성 SD 대서60지，수궤분위공백조、모형조、양성（금강등효낭）조、금강등구복액저、중、고제량조。실험제1천，제공백조외，기여각조대서용무파비타마취，채용쌍측수란관주입30%분분효장생리염수용액，제작대서분강염모형。조모후정상조화모형조 ig 급여순정수，기여각조 ig 급여약물，기중양성조일급약량위540 mg·kg-1，금강등구복액저、중、고제량조일급약량분별위：15 mg·kg-1、30 mg·kg-1、60 mg·kg-1，매천1차，공 ig 치료20천。제21천단경처사동물，ELISA 법측정각실험조대서혈장 IgA、IgM 화 IgG 함량；부취자궁，칭중후주병리형태분석。결과：여정상조비교，모형조대서자궁중량계수[（11.7±1.92） mg·g-1]겁현저증대（P<0.01），혈장IgA[（27.99±5.49）μg·mL-1]、IgM[（21.94±1.98）μg·mL-1]화 IgG[（4.85±1.97）μg·mL-1]함량균유겁현저감소（P<0.01）；자궁염증성병변현저가중；여모형조비교，금강등구복액조가현저감소대서자궁중량계수（P<0.05），증가혈장 IgA、IgM 화 IgG 함량（P<0.05），차능감경자궁염증성병변。결론：금강등구복액가통과조절대서혈장면역구단백농도이대만성분강염산생치료작용。
Objective: To study the therapeutic effect on rat chronic pelvic inflammatory disease of bullbrier polysaccharide. Methods: unmated SPF 60 female SD rats were randomly divided into control group, model group, positive group (Bullbrier capsules) group, bullbrier polysaccharide low, medium and high dose groups. On the 1d of experiment, except the blank group, the rest of the rats were anesthetized with amyl barbiturate, phenol 30% slurry injection of saline solution was injected from bilateral tubal to make rats pelvic inflammatory disease model. After being modeled, the normal group and model group ig given pure water, the positive group were given bullbrier dose of 540 mg·kg-1, polysaccharide of bullbrier of low, medium and high dose groups were given of dose: 15 mg·kg-1, 30 mg·kg-1, 60 mg·kg-1, a total ig 20 days of treatment. On the 21th days, rats were sacrificed, Elisa method was used for the determination of the experimental rats plasma IgA, IgM and IgG levels; taken uterus, after being weighed, pathological mor-phological analysis were done. Results: Compared with the normal group, model group uterine weight coef-ficient [(11.7±1.92) mg·g-1] was significantly increased (P<0.01), plasma IgA [(27.99±5.49) μg·mL -1], IgM [(21.94±1.98) μg·mL-1] and IgG[(4.85±1.97) μg·mL-1] content are extremely significantly reduce(P<0.01); the uterine inflammatory lesions were significantly heavier; compared with model group, Smilax polysaccharides can significantly reduce the weight of the rat uterus coefficient(P<0.05), increased plasma IgA, IgM and IgG levels (P<0.05), can reduce the uterine inflammatory lesions. Conclusion: Bullbrier polysaccharide can treat chronic pelvic inflammatory disease by adjusting the concentration of rat plasma immunoglobulin.
